Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) was the target of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 736,700 shares, an increase of 51.3% from the October 31st total of 487,000 shares. Based on an average daily trading volume, of 112,200 shares, the short-interest ratio is currently 6.6 days. Approximately 3.9% of the company's shares are short sold.

Vigil Neuroscience Stock Up 7.4 %

NASDAQ VIGL traded up $0.17 on Friday, reaching $2.47. The stock had a trading volume of 338,260 shares, compared to its average volume of 236,064. The stock has a fifty day moving average price of $3.40 and a two-hundred day moving average price of $3.63. Vigil Neuroscience has a 12-month low of $2.08 and a 12-month high of $6.06. The firm has a market capitalization of $100.97 million, a price-to-earnings ratio of -1.20 and a beta of 1.92.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Guggenheim reduced their price target on shares of Vigil Neuroscience from $17.00 to $16.00 and set a "buy" rating on the stock in a research report on Wednesday, August 14th. HC Wainwright restated a "buy" rating and issued a $17.00 target price on shares of Vigil Neuroscience in a research report on Friday, November 8th. JMP Securities reiterated a "market outperform" rating and set a $22.00 price target on shares of Vigil Neuroscience in a report on Tuesday. Finally, Wedbush raised their price objective on Vigil Neuroscience from $23.00 to $24.00 and gave the stock an "outperform" rating in a research report on Friday, November 8th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $16.60.

Institutional Investors Weigh In On Vigil Neuroscience

Institutional investors and hedge funds have recently modified their holdings of the company. Point72 Asset Management L.P. increased its stake in Vigil Neuroscience by 7.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company's stock worth $5,440,000 after buying an additional 115,000 shares during the period. Vanguard Group Inc. increased its position in shares of Vigil Neuroscience by 11.9% during the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company's stock worth $3,050,000 after acquiring an additional 95,276 shares during the period. Ensign Peak Advisors Inc raised its stake in shares of Vigil Neuroscience by 72.8% in the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company's stock valued at $1,580,000 after acquiring an additional 166,442 shares in the last quarter. abrdn plc purchased a new position in Vigil Neuroscience in the third quarter valued at $799,000. Finally, Geode Capital Management LLC grew its stake in Vigil Neuroscience by 41.9% during the 3rd quarter. Geode Capital Management LLC now owns 226,083 shares of the company's stock worth $769,000 after purchasing an additional 66,712 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company's stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.